IPO - Profile


We are a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 6,700,000 Positive High 28.9%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 16 Jul, 2021

Offer 16 Jul, 2021

Look Ahead

Lock Up Expiry Jan 16, 2022

IPO Terms

Offer Price $15.00
Offer Size 6M

Market Sentiments

Stock Price